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ProteomicMany in vitro data have shown that the efﬁcacy of several opioid drugs is correlated with differential
mu-opioid (MOP) receptor phosphorylation. Label-free semiquantitative on-line nanoﬂow liquid
chromatography–tandemmass spectrometry (nanoLC–MS/MS) analyses were performed to compare
the endogenous MOP receptor phosphorylation patterns of mice administered with morphine,
etonitazene and fentanyl. The analysis identiﬁed S363, T370 and S375 as phosphorylated residues
in the carboxy-terminus. Only T370 and S375 were regulated by agonists, with a higher propensity
to promote double phosphorylation for high efﬁcacy agonists. Our study provides conﬁrmation that
differential agonist-driven multi-site phosphorylation of MOP receptor occurs in vivo and validate
the use of MS to study endogenous GPCR phosphorylation.
 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Opioids, acting through G-protein coupled receptors (GPCR), are
the most effective drugs for the treatment of moderate to severe
pain but improving their use is still a matter of concern as many
undesirable effects limit their clinical utility. Moreover prolonged
opiate administration is associated with tolerance and pain hyper-
sensitivity [1–3]. Phosphorylation of the intracellular domain of
GPCR is a key component of the regulation of their function, playing
a well-established role in desensitization and internalization [3,4].
Recent studies indicate that differential agonist/cell-dependent
phosphorylation patterns behave as signaling barcodes driving the
speciﬁcity of cell response [5–8]. This mechanism could contribute
to the differential effects of opioid drugs used in pain management,
as suggested recently [9]. However, the analysis of MOP receptor
phosphorylation has been so far restricted to selected phosphoryla-
tion sites by using phospho-speciﬁc antibodies and thus a fullcharacterization of the in vivo phosphorylation pattern of the recep-
tor upon stimulation by different agonists is still lacking.
In vitro MOP receptor phosphorylation has been studied by
site-directed mutagenesis [10,11], phosphosite-speciﬁc antibodies
[12] and, more recently, mass spectrometry (MS) analysis [13–17].
Overall, data indicate that variation in the efﬁcacy of several opioid
drugs in terms of desensitization, arrestin recruitment and internal-
ization is correlated to differential MOP receptor phosphorylation,
involving diverse GRK or second-messenger kinases [15,18–20].
Phosphorylation of the MOP receptor occurs primarily at S363 and
within a cluster of serine and threonine residues
(370TREHPSTANT379) in the cytoplasmic tail (Fig. 1). Rodent S363
(or S365 in human) is constitutively phosphorylated and not subject
to regulation by agonists in transfected cells [11,12,16,17,21], while
a sequential and agonist-dependent differential phosphorylation
occurs in the 370TREHPSTANT379 cluster. S375 is phosphorylated
upon stimulation with both partial agonists such as morphine and
high efﬁcacy agonists such as DAMGO, but only the latters are able
to promote additional phosphorylation on T370, T376 and T379
[15,22]. The demonstration of poly-phosphorylation on single
370TREHPSTANT379 peptides was given by mass spectrometry anal-
yses that identiﬁed peptides doubly or triply phosphorylated on
both T370 and S375, and another residue [16,17]. In cell lines, the
phosphorylation of S375 by morphine is proposed to be mediated
for a signiﬁcant part by GRK5 while the phosphorylation of S375,
T370, T376 and T379 by DAMGO involves GRK2/3 isoforms
Fig. 1. Mass spectrometry coverage of the mouse brain MOP receptor sequence. The schema represents the secondary structure of the mouse MOP receptor. Colored symbols
indicate the protein sequence covered by nanoLC–MS/MS. The phosphorylated residues identiﬁed by nanoLC–MS/MS are represented in black symbols with white characters,
and are numbered in blue. Additional putative phosphoacceptor sites reported in the literature are numbered in black. Thick outlined circles indicate the trypsin cleavage
sites, with light gray outline for missed cleavages. pm, plasma membrane. The table gives the list of the MOP receptor peptides identiﬁed by nanoLC–MS/MS with a Mascot
score >24. Theo. mass., theoretical mass (Da); MC, missed cleavage; il, intracellular loop; C-term; carboxy-terminal intracellular tail.
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S375, results in impaired b-arrestin recruitment and MOP receptor
internalization [11,15,16], and in loss of morphine, but not
DAMGO, -induced desensitization of cAMP and ERK pathways
[23]. However, no effect on met-enkephalin-induced GIRK desensi-
tizationwas recently reported, thus questioning the role of this clus-
ter in desensitization [22,24].
In vivo MOP receptor phosphorylation is less well documented.
Immunoprecipitation of MOP receptor from the mouse brain [25],
followed by phosphosite-speciﬁc immunodetection, demonstrated
that the endogenous receptor is phosphorylated on S375 upon
morphine, fentanyl or etonitazene administration, with additional
phosphorylations on T370 and T379 only in the case of fentanyl
and etonitazene treatment [9,18,26]. Constitutive phosphorylation
of S363, without regulation by agonist treatment, was also evi-
denced [21]. An increase in MOP receptor phosphorylation within
the striatum of mice administered with fentanyl has also been
revealed by immunochemistry using an antibody raised against a
peptide with double phosphorylation on T370 and S375 [27].
Studies in GRK knock-out mice indicate that GRK5 is selectively
involved in morphine-induced phosphorylation of S375 [18] and
that GRK3 contributes to S375 phosphorylation induced by fen-
tanyl and, to a lesser extent, by morphine [9].
Mass spectrometry has been used as an alternative to
phospho-site speciﬁc antibodies to study GPCR phosphorylation
in heterologous cellular models [5,7,13–17]. It is a powerful tech-
nology offering the advantage over antibodies to allow the analysis
of all the putative phosphoacceptor sites and the identiﬁcation of
new post-translational modiﬁcations, as well as the demonstration
of multi-site phosphorylation on a single receptor. However its
usefulness for the characterization of low abundance native recep-
tors is only beginning to be evaluated [9]. In the present study we
have applied a mass spectrometry-based approach to analyze the
endogenous phosphorylation pattern of MOP receptor following
acute administration of different classes of opioid drugs in mice.
2. Methods
2.1. Materials
Morphine hydrochloride was obtained from Merck (Darmstadt,
Germany), fentanyl citrate from Rotexmedica (Trittau, Germany),and etonitazene hydrochloride from Sigma–Aldrich (Steinheim,
Germany). Drugs were dissolved in physiological saline and
injected subcutaneously (s.c.) in a volume of 10 ml kg1.
2.2. Animal welfare and ethical statement
The C57BL6/J mice were obtained from Charles River (Sulzfeld,
Germany). Knock-in mice expressing the phospho-deﬁcient
(S375A) MOP receptor mutant were previously described [26].
Animals were housed under a 12 h light–dark cycle with ad libitum
access to food and water. All animal care and experimental proce-
dures were approved by the Thuringian state authorities and com-
plied with EC regulations for the care and use of laboratory
animals. All studies involving animals are reported in accordance
with the ARRIVE (Animal Research: Reporting In Vivo
Experiments) guidelines. A total of 14 mice were used.
2.3. In vivo MOP receptor immunoprecipitation
30 minafter s.c. administrationof saline,morphine (10 mg kg1),
fentanyl (0.1 mg kg1) or etonitazene (0.1 mg kg1), mice were
anesthetized by isoﬂurane, killed by cervical dislocation, and brains
(without cerebellum) were quickly dissected and processed for
immunoprecipitationwith thephosphorylation-independent rabbit
monoclonal anti-MOP receptor antibody (UMB-3) as previously
described [9,25].
2.4. SDS–PAGE and immunoblotting
UMB-3 immunoprecipitates from one brain per condition,
including a control with no brain extract (UMB-3 alone), were
boiled for 5 min at 100 C and then alkylated in 90 mM iodoac-
etamide for 30 min in the dark. 2 ll from each brain extract were
pooled and separated by SDS–PAGE on 10% polyacrylamide gels.
The UMB-3 immunoprecipitates intended for MS analysis were
run on the same gel. The part of the gel for immunoblotting was
transferred to PVDF membrane and processed under standard con-
ditions in Tris–Buffered Saline (20 mM Tris–HCl, pH 7.5, 137 mM
NaCl) containing 0.2% Tween and 5% non-fat milk. The MOP recep-
tor was detected with a guinea pig anti-MOP receptor antibody
(Neuromics, USA) followed by a peroxydase-conjugated goat
anti-guinea pig antibody (Jackson Immunoresearch Laboratories,
L. Moulédous et al. / FEBS Letters 589 (2015) 2401–2408 2403USA) by using the ECL2 Western blotting substrate (Thermo Fisher
Scientiﬁc, France).
Immunoblotting from brains of wild-type and
phospho-deﬁcient S375A MOP receptor mice injected (30 min,
s.c.) with etonitazene 0.1 mg kg1 were performed as previously
described [26]. The blot was probed with guinea pig anti-pT370
and anti-p375, and with phosphorylation-independent guinea pig
anti-MOP receptor antibody to control gel loading, including a
stripping step between each blot.
2.5. NanoLC–MS/MS analysis
Gels were stained with colloidal Coomassie blue for 24 h. A
band was excised at the molecular weight of the MOP and sub-
jected to in-gel tryptic digestion using modiﬁed porcine trypsin
(Promega, France) at 20 ng ll1. The dried peptide extracts were
then analyzed by on-line nanoLC using an Ultimate 3000 System
(Dionex, Amsterdam, The Netherlands) coupled to an
ETD-enabled LTQ Orbitrap Velos mass spectrometer (Thermo
Fisher Scientiﬁc, Bremen, Germany) as previously described [17]
except for the MS/MS acquisition mode which was an alternative
decision tree-driven collision-induced dissociation (CID)/electron
transfer dissociation (ETD) fragmentation acquisition instead of
two consecutive CID and ETD acquisitions. The survey scan MS
was performed in the Orbitrap on the 300–2000 m/z mass range
with the resolution set to a value of 60000 atm/z 400. The 20 most
intense ions per survey scan were selected for subsequent CID/ETD
fragmentation, and the resulting fragments were analyzed in the
linear trap (LTQ). The settings for the data-dependent decision
tree-based CID/ETD method were as follows: ETD was performed
instead of CID if charge state was 3 and m/z less than 650, or if
the charge state was 4 and the m/z less than 900, or if the charge
state was 5 and the m/z less than 950. ETD was performed for all
precursor ions with charge states >5. The normalized collision
energy was set to 35% for CID. The reaction time was set to
100 ms and supplemental activation was enabled for ETD. Triple
technical replicates were performed in some conditions.
2.6. Database search and label-free determination of MOP receptor
phosphopeptide relative abundance ratio
Peak list extraction from Xcalibur raw ﬁles was automatically
performed using Proteome Discoverer software (version 1.4,
Thermo Fisher Scientiﬁc). The parameters set for creation of the
peak lists were: parent ions in the mass range 300–5000 and no
grouping of MS/MS scans. The non-fragmented ﬁlter was used to
simplify ETD spectra with the following settings: the precursor
peak was removed within a 4-Da window, charged reduced precur-
sors were removed within a 2-Da window, and neutral losses from
charged reduced precursors were removed within a 2-Da window
(the maximum neutral loss mass was set to 120 Da). Peak lists
were searched against SwissProt database with taxonomy Mus
musculus (16611 sequences) and using Mascot software (version
2.3.01, Matrix Science, London, UK). Cysteine carbamidomethyla-
tion was set as a ﬁxed modiﬁcation and methionine oxidation,
N-terminal acetylation and serine/threonine/tyrosine phosphory-
lations as variable modiﬁcations. Up to three missed trypsin cleav-
ages were allowed. Mass tolerances in MS and MS/MS were set to
10 ppm and 0.6 Da, respectively. Mascot results were parsed with
the in-house developed software Mascot File Parsing and
Quantiﬁcation (MFPaQ) version 4.0 [28], and protein hits were
automatically validated if they satisﬁed one of the following crite-
ria: identiﬁcation with at least one top ranking peptide of a mini-
mal length of six amino acids and with a Mascot score higher
than the identity threshold at P = 0.001 (99.9% probability) or at
least two top ranking peptides each of a minimal length of sixamino acids and with a Mascot score higher than the identity
threshold at P = 0.05 (95% probability). The peptides of MOP recep-
tor were considered as valid if their Mascot ion scores were higher
than 24 (P value <0.05), if not the identiﬁcation was conﬁrmed by
manual interpretation of corresponding MS/MS data. The phospho-
rylation site localization of identiﬁed phosphopeptides was per-
formed by phosphoRS algorithm 3.1 [29] implemented in
Proteome Discoverer. A site localization probability of at least
0.75 was used as the threshold for the phosphoresidue localization.
Peak areas were automatically measured from extracted ion chro-
matograms of each peptide (sum of all observed charge states) in
thenanoLC–MS raw ﬁle using the label-free module of MFPaQ soft-
ware. To calibrate the amounts of MOP receptor in the different
conditions, normalization was performed based on the sum of
the extracted ion chromatogram areas of all identiﬁed MOP recep-
tor peptides. In the case where a peptide was missing in one sam-
ple, a value corresponding to the peak area of the peptides of the
lowest abundance (1st percentile) among all the peptides identi-
ﬁed in the sample was assigned to the missing data.
3. Results
3.1. NanoLC–MS/MS analysis of MOP receptors from mouse brain
The UMB-3 antibody has been previously demonstrated to
speciﬁcally immunoprecipitate the MOP receptor from mouse
brain as a broad band in the 70–80kDa range [25,26]. It was efﬁ-
cient enough to enable detection of MOP receptor peptides by mass
spectrometry from only one mouse brain [9]. This prompted us to
characterize the in vivo phosphorylation patterns of MOP receptors
after treatment of mice (30 min, s.c.) with saline, morphine
(10 mg kg1), fentanyl (0.1 mg kg1) or etonitazene (0.1 mg kg1).
An example of SDS–PAGE separation of UMB-3 immunopuriﬁed
MOP receptor is given in Fig. 2, as well as the corresponding
Western blot run on the same gel and loaded with a small amount
of sample and with a control without brain extract. A speciﬁc band
was visible on the immunoblot at the MOP receptor expected size.
After in-gel tryptic digestion of the excised band corresponding to
the position of the receptor, nanoLC–MS/MS decision tree-driven
CID/ETD analyses and Mascot database searches, including puta-
tive phosphorylation modiﬁcation, identiﬁed the MOP receptor
sequence with 15% coverage. This included half of the 2nd intracel-
lular loop (il2) and nearly all the amino acids of the C-terminal tail
allowing the characterization of 12 putative phosphorylation sites
(Fig. 1). As expected because of the abundance of lysine and argi-
nine residues in il1 and il3, resulting in the generation of short
2–3 amino acid-long peptides, these regions were not covered.
Also, the peptide 175ALDFR179 in il2, although always detected,
was not considered in the study because of its low Mascot score.
Overall, 7 among the 11 residues reported in the literature to be
potentially phosphorylated in MOP receptors were covered. In the
C-terminal part, unphosphorylated and monophosphorylated
forms of S363 (Fig. 3A) and S375 (Fig. 3C) containing peptides were
identiﬁed by CID/ETD fragmentation analyses. As T370 is sur-
rounded by two arginines, only phosphorylated forms of T370 con-
taining peptides could be detected owing to miscleavages due to
phosphate hindrance to trypsin activity (Figs. 1 and 3B).
Interestingly, double phosphorylation on T370 and S375 was
unambiguously identiﬁed on the 368QNTREHPSTANTVDR382 pep-
tide (Fig. 3D). The 166YIAVCHPVK174 peptide in il2 and the
383TNHQLENLEAETAPLP398 peptide at the C-terminal extremity,
which were consistently detected in all conditions, were never
found phosphorylated. Also, no other phosphorylation than S363
was detected in the 349EFCIPTSSTIEQQNSAR365 peptide. In samples
from agonist-treated mice, MS analyses identiﬁed the same
unphosphorylated and phosphorylated peptides as in saline mice,
Fig. 2. Western blot image (left) and Coomassie blue-stained gel (right) of UMB-3-immunopuriﬁed MOP receptor from mouse brain. The immunoprecipitated material from
brain of mice injected (30 min, s.c.) with saline, morphine (10 mg kg1), etonitazene (0.1 mg kg1) or fentanyl (0.1 mg kg1) was separated by SDS–PAGE. Left, immunoblot
using anti-MOP antibody. The ‘‘alone’’ lane corresponds to a control immunoprecipitation performed in the absence of brain extract. The ‘‘+ brain extract’’ lane corresponds to
a pool of small aliquots of each extract. Right, Coomassie blue staining of the immunoprecipitated material. Rectangles delimitate the pieces of gel containing the MOP
receptor and excised for nanoLC–MS/MS analysis.
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lated species. However, agonist treatment increased the abun-
dance of several phosphorylated peptides compared to saline.
3.2. Relative label-free quantiﬁcation of agonist-induced
phosphorylation of endogenous MOP receptor
The label-free module of the MFPaQ software was used to calcu-
late the relative abundance of phosphorylated and unphosphory-
lated peptides in the agonist-treated conditions relative to
saline (Fig. 4). No difference between saline and agonist-treated
groups was observed for the S363-phosphorylated form of
349EFCIPTSSTIEQQNSAR365 or the T370-phosphorylated form of
368QNTREHPSTANTVDR382, indicating that these peptideswere con-
stitutively phosphorylated. In contrast, the agonists were found to
slightly increase thephosphorylation on S375and to exhibit a differ-
ential propensity for driving double phosphorylation on S375 and
T370. The S375-phosphorylated form of the 372EHPSTANTVDR382
peptide was 1.9 ± 0.6, 2.3 ± 0.8 and 2.6 ± 0.9-fold more abundant in
etonitazene, morphine and fentanyl treated mice than in saline
group, respectively. A signiﬁcant increase in the abundance of
pT370/S375 diphosphorylated 368QNTREHPSTANTVDR382 peptide
was observed in mice injected with fentanyl (2.7 ± 0.1) and etoni-
tazene(6.2 ± 0.3), but not in themorphine group(1.5 ± 0.7). Since
the amount of receptor species withmonophosphorylation on T370
remained unchanged in all conditions, it can be concluded that
diphosphorylated species result from the phosphorylation of T370
on a receptor previously phosphorylated on S375. This hierarchical
phosphorylation was conﬁrmed in phospho-deﬁcient S375A MOP
receptor mice administered with etonitazene, in which the loss of
S375phosphorylationwas accompaniedbyadecrease in T370phos-
phorylation, as compared towild-typemice (Fig. 5). OurMS analysis
thus conﬁrms the differential capacity of agonists to induce MOP
receptor phosphorylation and provides evidence that high efﬁcacy
opioids trigger multiphosphorylation on a single peptide.
4. Discussion
This work is the ﬁrst detailed mass spectrometry analysis of the
in vivo phosphorylation of a brain GPCR. To our knowledge, only
one other study has previously reported the MS identiﬁcation ofphosphorylation sites in a native GPCR, the N-formyl peptide
receptor (FPR1), but from ex vivo stimulated human blood neu-
trophils [30]. The present phosphoproteomic analysis of native
MOP receptor not only allowed an accurate identiﬁcation of the
residues phosphorylated in vivo and their regulation by agonist
treatments, but also conﬁrmed that differential agonist-induced
multiple phosphorylation on a single receptor occurs in vivo.
The analysis covered half of the putative phosphorylation sites
present in the intracellular domains of the mouse endogenous
MOP receptor and identiﬁed S363, T370 and S375 as phosphory-
lated residues, in accordance with MS analyses in transfected cel-
lular models [13,16,17]. Only the phosphorylation of T370 and
S375 was increased by agonist administration.
In contrast to in vitro MS studies reporting phosphorylation of
the 354TSST357 motif upon agonist stimulation of transfected mouse
or rat receptors [13,16], we did not identify phosphorylated resi-
dues other than S363 in the 349EFCIPTSSTIEQQNSAR365 peptide
from the endogenous mouse MOP receptor. Though differences in
detection sensitivity between native preparation and overex-
pressed receptors cannot be excluded, this suggests that the
354TSST357 motif is not a primary phosphorylation cluster in vivo.
In this sense, alanine mutations within this motif show unconsis-
tent results in the literature: no effect on MOP receptor phospho-
rylation level [11,31], desensitization [24,31] and internalization
[16]; decreased phosphorylation and desensitization in the case
of the rat S355A/T357A receptor mutant [32]; impact on agonist
dissociation kinetics [24].
In agreement with the literature [20], phosphorylation of S363
was not found to be regulated by in vivo administration of mor-
phine, etonitazene and fentanyl, indicating constitutive phospho-
rylation of this residue in native MOP receptors. Upon
administration of morphine, etonitazene or fentanyl, a higher pro-
portion of MOP receptor phosphorylated on S375 and doubly phos-
phorylated on S375 and T370 was detected compared to animals
injected with saline, whereas the proportion of MOP receptor only
phosphorylated on T370 was unchanged. Along with the decrease
of etonitazene-induced T370 phosphorylation observed in
phospho-deﬁcient S375AMOP receptor mice, these results indicate
that the hierarchical multi-site phosphorylation involving a pri-
mary step of S375 phosphorylation and described in cellular mod-
els [15] also occurs in vivo.
Fig. 3. NanoLC–MS/MS analysis of MOP receptor phosphorylation. (A) The CID MS/MS spectrum of the monophosphorylated peptide, 349-EFCamIPTSSNIEQQNpSTR-365
(doubly charged precursor ion, MH2+, at m/z 1024.4419) displays series of b- and y-ions indicating that S363 is phosphorylated. (B) The ETD MS/MS spectrum of the
monophosphorylated peptide, 368-QNpTREHPSTANTVDR-382 (triply charged precursor ion, MH3+, at m/z 602.6024) displays series of c- and z-ions indicating that T370 is
phosphorylated. (C) The ETD MS/MS spectrum of the monophosphorylated peptide, 372-EHPpSTANTVDR-382 (triply charged precursor ion, MH3+, at m/z 436.1857) displays
series of c- and z-ions indicating that S375 is phosphorylated. (D) The ETD MS/MS spectrum of the diphosphorylated peptide, 368-QNpTREHPpSTANTVDR-382 (triply charged
precursor ion, MH3+, at m/z 629.2578) displays series of c- and z-ions indicating that T370 and S375 are phosphorylated. For all spectra, phosphorylation site-determining
ions and the corresponding peaks are highlighted in red and those which conﬁrm the phosphorylation localization and exclude other potential sites are indicated in blue. P:
loss of H3PO4 from sequence ions. pS, pT: phosphorylated serine or threonine residues. Cam: carbamidomethylated cysteine residue.
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Fig. 4. Relative abundance ratio (compared to saline) of unphosphorylated, monophosphorylated and diphosphorylated MOP receptor peptides identiﬁed in mice treated
(30 min, s.c.) with saline (n = 4), morphine 10 mg kg1 (n = 3), fentanyl 0.1 mg kg1 (n = 3) or etonitazene 0.1 mg kg1 (n = 4). Relative quantiﬁcation of peptides was
performed with the label-free module implemented in the MFPaQ v4.0 software. To enable comparison between samples, the peak area of each peptide in a sample was
normalized to the sum of the extracted ion chromatogram area of all identiﬁed MOP receptor peptides. Bars correspond to the relative ratio of normalized peak intensities of
each group over saline group, and are expressed as mean ± SEM of the number of mice extracts in which the peptide was detected (numbers indicated in each bars). *P < 0.05,
⁄⁄⁄P < 0.001, different from the corresponding peptide in saline condition (1-way ANOVA followed by Dunnett’s post-test).
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induce double phosphorylation whereas morphine effect was not
statistically signiﬁcant, conﬁrming in vitro studies reporting that
higher efﬁcacy agonists induce a higher level of multi-site phos-
phorylation [15]. However, additional phosphorylations on resi-
dues T376 and T379 have been identiﬁed by phosphosite-speciﬁc
antibodies in cells [15] and/or in vivo [9], and triple phosphoryla-
tion on the 366IRQNTREHPSTANTVDR382 peptide was detected by
MS analysis, however upon a prolonged agonist treatment
(180 min) of recombinant cells [16]. Our mass spectrometry anal-
ysis did not clearly identify additional phosphorylation on T376
or T379, pointing to the necessity of improving the sensitivity of
the method for detecting the presence of low-abundant triple (or
more) phosphorylated peptides in vivo. Applying SRM (single reac-
tion monitoring) targeted proteomics or phosphopeptide enrich-
ment could be envisaged, but a more prolonged treatment with
agonists or the use of higher doses could also potentially increase
the amount of multiphosphorylated species.
Beside the major phospho-residues identiﬁed in the present
study, a number of other putative phosphorylation sites have been
described in the literature on the basis of mutagenesis studies or
phospho-site immunodetection in recombinant cell models.
Among them, two are covered by our analysis but were not found
to be phosphorylated in the native receptor: Y166 in the DRYmotif,
which necessitates costimulation of the cells by DAMGO and EGFto be phosphorylated and contributes to reduce G-protein coupling
[33], and T394, the mutation of which induces a loss in MOP recep-
tor phosphorylation, desensitization and chronic opioid-induced
adenylyl cyclase superactivation [31,34,35]. These indirectly char-
acterized phospho-acceptor sites, if regulated in vivo, should rep-
resent minor species that are below the detection level of our MS
analyses.
As illustrated above, studies in cellular models have helped
understanding the role of phosphorylation in the regulation of
MOP receptor activity but have also provided a large variety of
data, depending on cells and methods used, which are sometimes
difﬁcult to reconcile, raising thus the question of their physiologi-
cal relevance and highlighting the necessity to work closer to the
native environment. Now that the proof of feasibility of applying
semiquantitative label-free proteomic approach for analyzing
in vivo MOP receptor phosphorylation is demonstrated, it will offer
the opportunity to examine what happens in animals after acute
and prolonged treatments with different classes of opioid drugs,
upon heterologous regulation or in pathological conditions.
Therefore, as a complement to the use of phosphosite-speciﬁc anti-
bodies, the efﬁciency of which depends on their relative selectivity
and afﬁnity, in vivo proteomic approach is susceptible to provide a
more quantitative and in-depth overview of the phosphorylation of
native GPCR and paves the way for future exploration of other
endogenous post-translational modiﬁcations.
Fig. 5. Western blot image of UMB-3-immunopuriﬁed MOP receptor from brains of
wild-type and phospho-deﬁcient S375A MOP receptor mice injected (30 min, s.c.)
with etonitazene 0.1 mg kg1. The blot was probed with anti-pT370 (ﬁrst panel),
anti-p375 (second panel) and with phosphorylation-independent anti-MOP recep-
tor antibody.
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